Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 12/20 | 0.78 |
| ▸ | FURIN | P09958 | 1/20 | 0.56 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536446 | 1.00 | OPRL1 (0.78) | OPRL1FURINQRFPRNPBWR1 | |
| SCHEMBL31536447 | 1.00 | OPRL1 (0.78) | OPRL1FURINQRFPRNPBWR1 | |
| SCHEMBL31536444 | 0.93 | OPRL1 (0.78) | OPRL1FURINQRFPR | |
| SCHEMBL31536443 | 0.93 | OPRL1 (0.78) | OPRL1FURINQRFPR | |
| SCHEMBL29623262 | 0.93 | OPRL1 (0.78) | OPRL1FURINQRFPR | |
| Nociceptin-Nh2 SCHEMBL30033176 | 0.92 | OPRL1 (0.79) | OPRL1 | |
| Nociceptin SCHEMBL29358223 | 0.88 | OPRL1 (0.79) | OPRL1 | |
| SCHEMBL27915864 | 0.84 | OPRL1 (0.54) | OPRL1 | |
| SCHEMBL30974017 | 0.82 | OPRL1 (0.62) | OPRL1 | |
| SCHEMBL30980377 | 0.81 | OPRL1 (0.58) | OPRL1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702044-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2026-03-04 | — | — | EP | claimed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| CN-115219022-B | Calibration method for shot noise limit of time domain balanced homodyne detector | 山西大学 | 2025-03-07 | — | — | CN | claimed |
| WO-2025049979-A1 | HYDROPHOBICALLY INTERSPACED CHARGED PEPTIDES FOR PREVENTING OR TREATING APOE AND/OR AMYLOID BETA PATHOLOGIC INTERACTION IN ALZHEIMER'S DISEASE AND RELATED DEMENTIAS | NEW YORK UNIVERSITY (US) | 2025-03-06 | — | — | WO | claimed |
| US-20240391889-A1 | ANTIMICROBIAL COMPOUNDS AND THE METHODS OF USE | Middle Tennessee State University | 2024-11-28 | — | — | US | claimed |
| WO-2024223742-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B PHARMACEUTICALS GMBH (DE) | 2024-10-31 | — | — | WO | claimed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | claimed |
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | claimed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | claimed |
| US-20230295234-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-09-21 | — | — | US | claimed |
| EP-4214221-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | claimed |
| EP-4214220-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | claimed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | claimed |
| CN-115989236-A | Antimicrobial peptidomimetics | 斯派西斯公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115989237-A | Antimicrobial peptidomimetics | 斯派西斯公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2023055999-A1 | ANTIMICROBIAL COMPOUNDS AND THE METHODS OF USE | Middle Tennessee State University (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2023012319-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-02-09 | — | — | WO | claimed |
| EP-3328877-B1 | PEPTOID | THE UNIV OF DURHAM (GB) | 2022-08-24 | — | — | EP | claimed |
| WO-2022028737-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391889-A1 | ANTIMICROBIAL COMPOUNDS AND THE METHODS OF USE | VIP, FPR1, NOD2 | OPRL1 731/4885FURIN 850/4885QRFPR 49/4885 |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | OPRL1 88/4885FURIN 900/4885QRFPR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.